Substance / Medication

Cefuroxime sodium

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

133 trials linked to this intervention

133
Total Trials
32
Recruiting
17
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Exploring the safety and feasibility of intracameral Aprokam® (cefuroxime sodium) in pediatric cataract surgery.
Nucci Paolo, Lembo Andrea, Schiavetti Irene et al. · Int Ophthalmol · 2025
PMID: 39831915Observational
A Comparison of in-vitro Pharmacokinetics and Pharmacodynamics of Branded and Its Locally Produced Cefuroxime Sodium Againstand.
Du Mengjiao, Sun Tingting, Wang Xueting et al. · Drug Des Devel Ther · 2025
PMID: 40589447ObservationalFull text (PMC)
Comparison of HPLC and UV spectrophotometric methods for the determination of cefuroxime sodium in pharmaceutical products.
Vieira D C M, Salgado H R N · J Chromatogr Sci · 2011
PMID: 21801481Observational
Development and validation of a microbiological agar assay for determination of cefuroxime sodium in pharmaceutical preparations.
Schmidt Cleber A, Agarrayua Danielle A, Laporta Luciane V et al. · J Microbiol Methods · 2009
PMID: 19344741Observational
Preliminary In Vivo Ocular Tolerance Assessment of a Cefuroxime Sodium Suspension in Self-Emulsifying Oil.
Krzemińska Katarzyna, Wolska Eliza, Chorążewicz Juliusz et al. · Pharmaceutics · 2025
PMID: 41155956OtherFull text (PMC)
Kaolin-graphene carboxyl incorporated TiOas efficient visible light active photocatalyst for the degradation of cefuroxime sodium.
Rajan Mekha Susan, Yoon Minjoong, Thomas Jesty · Photochem Photobiol Sci · 2022
PMID: 35230675Other
[Influence of cefuroxime sodium on synaptic plasticity of parallel fiber-Purkinje cells in young rats].
He Hai-Yan, Ren Ying-Ge, Li Ling et al. · Zhongguo Dang Dai Er Ke Za Zhi · 2016
PMID: 27324547PreclinicalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cefuroxime sodium (substance)
SNOMED CT
48753004
UMLS CUI
C0701852

Clinical Data

This intervention maps to 17 entities in the Healos knowledge graph.

17
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
133
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.